Review

Robotic-assisted radical cystectomy: Literature review

Marcio Covas Moschovas a,*, Kulthe Ramesh Seetharam Bhat a, Cathy Jenson a, Vipul R. Patel a, Gabriel Ogaya-Pinies b, c

a Department of Urology, AdventHealth Global Robotics Institute, Celebration, FL, United States
b Department of Urology, Hospital Rey Juan Carlos, Madrid, Spain
c Lyx Instituto de Urologia, Madrid, Spain

Received 20 December 2019; received in revised form 25 February 2020; accepted 22 April 2020
Available online 3 July 2020

Abstract Radical cystectomy (RC) with pelvic lymph node dissection (PLND) is the standard treatment for localized muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC) with recurrence or high risk of progression. Also, the robotic approach to this type of surgery is well established in the literature. Our objective is to summarize in this manuscript the most relevant articles related to the robotic-assisted radical cystectomy for prostate cancer. We performed a literature review of articles describing the robotic approach to RC in patients with bladder cancer. Also, we described the procedure since the patient selection until the bladder removal. The reconstructive techniques were not included in this review. Twenty-five articles were used to divide our manuscript into key points such as preoperative patient selection and protocols, surgical technique, pathology report, oncological outcomes, complication rates, and quality of life after the procedure. Robotic-assisted radical cystectomy is feasible and safe with satisfactory oncological outcomes. The robotic approach is related to lower blood loss and fewer transfusion rates. However, when compared to open surgery, the use of this technology increases the operative time.

© 2021 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author.
E-mail address: marcio.doc@hotmail.com (M.C. Moschovas).
Peer review under responsibility of Second Military Medical University.

https://doi.org/10.1016/j.ajur.2020.06.007
2214-3882/© 2021 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Radical cystectomy (RC) with pelvic lymph node dissection (PLND) is the standard treatment for localized muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC) with recurrence or high risk of progression [1,2]. During the last 20 years, different authors described the benefits of robotic assistance during minimally invasive surgery for a variety of surgical techniques in urology [3], especially in procedures such as robotic-assisted radical prostatectomy (RARP) in terms of decreased morbidity and improved recovery time.

RC has always been associated with a high rate of perioperative complications ranging from 30% to 70% of the cases [4], and with a readmission rate up to 25% in the first 30 days after the surgery. Therefore, the natural evolution of the urologic surgery was to incorporate robotic assistance to this procedure [5]. In this context, Menon et al. [6] reported the first robotic-assisted radical cystectomy (RARC) with a nerve-sparing technique in 17 patients, and described a viable option for the treatment of bladder cancer (BCa).

Since the introduction of robotic technology to treat BCa, some authors in the literature performed comparisons between open and robotic radical cystectomies. The RARC has been shown to be equivalent to open radical cystectomy (ORC) in terms of oncological and functional outcomes [7]. However, only a few trials have presented evidence of similar intra- and perioperative complications [8–10].

2. Material and methods

We summarized in this manuscript a literature review of the most relevant articles reporting RARC for bladder cancer. However, the different reconstruction techniques after the bladder removal will be considered in a separate article, also described by our group.

2.1. Before the surgery

2.1.1. Patient selection

The current literature does not describe absolute contraindications for RARC. The standard contraindications apply to all patients, including coagulopathy, severe ascites, or advanced disease. Careful consideration should be given to those patients with significant pulmonary disease or severe obesity (BMI > 35 kg/m²), which may preclude them from tolerating a steep Trendelenburg position or prolonged pneumoperitoneum [5]. Moreover, high-complexity cases, such as patients with extensive intestinal adhesions, and previous pelvic radiotherapy, should be performed by an experienced surgeon [7].

2.1.2. Preoperative preparation

All patients undergoing RARC should be included in an enhanced recovery after surgery (ERAS) or a fast-track surgery program. Recognized differences to ERAS designed for RARC include a minimally invasive approach, less blood loss, avoidance of an epidural, earlier mobilization, and reduced postoperative analgesic requirements [11,12,13]. Other key principles of these protocols regard the preoperative patient education, optimization of nutrition, as well as standardized anesthetic and antiemetic regimens [11].

Mechanical bowel preparation is usually omitted for patients undergoing RARC [14]. A prospective randomized control trial (RCT) comparing bowel preparation versus no-bowel preparation for open RC shows no difference in terms of sepsis, wound infection, postoperative ileus, and hospital stay [2]. However, a fleet enema can be administered on the night before surgery because having a decompressed rectum helps create a wider space resulting in easier mobilization during the posterior dissection. Also, in case of an inadvertent rectal enterotomy, rectal decompression may help to facilitate a primary closure [3].

Vegetables should be avoided for 24 h before the surgery; otherwise, the nondigestible vegetables can be seeded into the peritoneum with spillage from the opened ileum during the intracorporeal urinary reconstruction [4]. In the case of an ileal conduit, the stoma site should be marked before the surgery, preferably with the help of a stoma therapist.

2.2. Technique

2.2.1. Patient’s positioning and trocar placement

The patient is placed in steep Trendelenburg position, the legs in low lithotomy, and the arms tucked to the body. Pads protect all extremities and articulations. An anti-slip surface is recommended to avoid the use of shoulder supports. With the da Vinci Xi® (Intuitive Surgical, Sunnyvale, California, USA), side docking is preferred, especially with female patients, allowing more accessible access to the perineum during the procedure.

The trocar placement is very similar to the robotic-assisted radical prostatectomy (RARP). Four robotic trocars are used, the camera trocar is placed 4–5 cm above the umbilicus, and the remaining three are placed as in Fig. 1, at least 8 cm away from each other, however, should be adapted to patient's anatomy. Two additional trocars are placed for the bedside assistant, a 12 mm trocar in the right flank, and a 5 mm trocar between the camera trocar and the right side robotic trocar. This...
5 mm trocar should be placed more cephalic to avoid clashing with the robotic arms. The patient is prepped and draped in the usual sterile-fashion, including the perineum. The Foley catheter is placed after the sterile field is set.

### 2.2.2. Cystoprostatectomy: Step by step

#### 2.2.2.1. Ureteral dissection

The first step is identifying the ureters at the common iliac artery crossing. Once the ureters are identified, the caudal release is performed with caution to avoid grasping, stretching, and excessively defat of the ureter. If coagulation is needed, pin-point bipolar energy should be used. Once the bladder insertion is reached, a distal Hem-o-lok® and a more proximal Hem-o-lok® with a pre-tied suture are applied to avoid urine spillage. The ureter is then transected, and the distal margin is sent for the frozen section (Fig. 2A).

#### 2.2.2.2. Posterior dissection

An incision is made in the peritoneum of the cul-de-sac. The fourth arm can then be used to retract the peritoneal reflection upward, resulting in better exposure. The fatty and fibrovascular tissue is dissected off the posterior peritoneal fold. When the seminal vesicles (SV) are identified, they are dissected down to their base, being careful not to perform an extensive lateral dissection of the SV if a neurovascular bundle (NVB) preservation is planned (Fig. 2B). Once the Denonvillier’s fascia is reached, it is sharply dissected in the midline, and the plane between the rectum and the prostate is created (Fig. 2C). At this point, using the toggling feature of the da Vinci Xi® endoscope to 30° up will allow better exposure and dissection of the plane to the posterior prostatic apex, as well as a better view laterally to continue the NVB preservation.

#### 2.2.2.3. Bladder pedicles

The anterior peritoneum is incised laterally to the medial umbilical ligaments, keeping the ligaments in place and taking the peritoneum down until the vas deferens. The lateral bladder space is created in the same way it is performed during a RARP until reaching the endopelvic fascia. The fascia is then opened, and the space is dissected by gently sweeping the fibers of the levator ani muscle laterally, and continuing down to the prostatic apex (Fig. 2D). At this point, the bladder pedicles are transected to join the lateral bladder space with the posterior space, using either a vessel sealer or Hem-o-lok® clips if preservation of the NVB is intended.

#### 2.2.2.4. NVB preservation

Patients who were potent preoperatively, with organ-confined disease, motivated to preserve their sexual function, will benefit from NVB sparing techniques. The NVB sparing begins with a dissection of the seminal vesicles. It is crucial to avoid the use of energy at this point. In this context, we perform this step using Hem-o-lok® clips for dissection of the bladder pedicles. The NVB preservation is continued at the opening of the Denonvillier’s fascia, finding the right plane to begin the release of the NVB from below. The NVB release from the prostate needs to follow the same principles as in the RARP: No energy and minimal traction. An interfascial plane between the prostate and the NVB is created at the level of the mid-prostate until the previously created posterior plane. The dissection is then continued in a retrograde fashion toward the base of the prostate to completely detach the NVB from the prostatic pedicle. The plane is then continued toward the apex by detaching the prostate from the NVB.

#### 2.2.2.5. Dorsal vein complex and urethra

The urachus and the median umbilical ligaments are dissected (Fig. 2E), and the posterior aspect of the bladder and prostate are exposed. Once the puboprostatic ligaments are reached, they are incised, and the dorsal vein complex (DVC) is ligated using a 0 Vicryl on a CT1 needle. The plane between the DVC and the urethra is gently developed to expose the anterior urethral wall. The anterior urethra wall is sharply transected with the scissors, a Hem-o-lok® clip is placed on the Foley catheter, and the catheter is cut distal to the clip, keeping the balloon inflated inside the bladder to avoid spillage of urine. The Foley catheter stump can be pulled back to expose the posterior urethra wall, which is divided, released from Figure 2. Intraoperative images. (A) Right ureter before clipping. Noticed the periureteral fat preservation. (B) Dissection of the left seminal vesicle (Green Arrow) and Denonvillier’s fascia in the back (Blue Arrow). (C) Seminal Vesicles are pulled up while the free edge of the Denovillier’s fascia is pulled down in order to create the space to dissect the posterior plane of the prostate. (D) Right lateral dissection. The endopelvic fascia is open, and the lateral aspect of the prostate (blue arrow) is gently pulled apart from the elevator ani muscle (green arrow). (E) Once the lateral plane is connected to the posterior plane by dissecting the bladder and prostatic pedicles, the urachus is divided.
the rectourethralis muscle and Denonvillier’s fascia, and the specimen released.

2.2.2.6. Specimen retrieval. The specimen is immediately bagged in an Endocatch bag. In a female patient, the specimen can be extracted through the opening in the anterior wall of the vagina. In male patients, after the bag is closed, the string of the Endocatch bag is transferred from the 12 mm assistant trocar to the 5 mm trocar, and pulled back through the trocar and clamped with a hemostat, preventing it from interfering with the rest of the surgery.

2.2.2.7. Considerations in female patients [11]. The same surgical technique, as aforementioned, is described for female patients in terms of bladder dissection and vascular control. However, in this group, we also perform the anterior vaginal resection, salpingectomy, and omentectomy, and in fact, having the bladder in place during the PLDN after the cystoprostatectomy specimen is bagged. In our view the bladder is undamaged, or has a very small injury, which could minimize the complications during the learning curve [15].

2.2.2.8. Lymph node dissection. We performed the PLND after the cystoprostatectomy specimen is bagged. In our view performing the PLND first doesn’t add any technical advantages, and in fact, having the bladder in place during the PLDN may require the use of the fourth arm to retract the bladder, compromising the use of the arm during this step [15].

The standard PLND during a cystoprostatectomy involves the bilateral removal of nodal tissue cranially up to the common iliac bifurcation, with the ureter being the medial border, and including the internal iliac, obturator fossa and external iliac nodes [1]. The extended PLND includes all lymph nodes in the region of the aortic bifurcation, presacral, and common iliac vessels medially to the crossing ureters.

The therapeutic value of PLND is under ongoing debate, and controversy exists concerning the optimal anatomic extent of PLND [16]. In a recent RCT the extended PLND failed to show an advantage over standard PLDN regarding recurrence-free survival, cancer-specific survival, and overall survival. Lymphoceles requiring intervention within 90 days after surgery was higher in the extended PLND group (8.6%) compared with the limited PLND group (3.4%; p = 0.04) [17].

2.3. Oncological outcomes

2.3.1. Positive surgical margins In a recent meta-analysis comparing RARC vs. ORC, five studies with more than 540 patients showed no differences in terms of positive surgical margins (PSM) (relative risk [RR] 1.16, 95% confidence interval [CI] 0.56–2.40), between the two different approaches [1]. The same conclusion was reached in a systematic review of the literature, where PSM ranged from 0 to 12% in the different studies, but no difference was observed between RARC and ORC [5].

2.3.2. Recurrence and progression The RAZOR trial compared the 2-year progression-free survival of RARC with ORC, showing non-inferiority for the robotic approach (difference 0.7%, 95% CI 9.6%–10.9%; p = 0.001) [18]. Regarding the recurrence rate, in a systematic review and meta-analysis previously mentioned, three studies with 458 patients showed no difference between RARC and ORC (RR 0.94, 95% CI 0.69–1.29) [19].

In a European multi-institutional series, unusual recurrence patterns were not identified. Peritoneal carcinomatosis and metastasis at the port site represented only 0.7% and 0.3% of the recurrences, respectively. The recurrence patterns in RARC appeared similar to those in the ORC series. Distant recurrences most frequently occurred in the bones, lungs, and liver, whereas pelvic lymph nodes were the most frequent site of local recurrence [11].

2.3.3. Survival rates In a recent study published by the Mayo Clinic, for 10 years, 481 patients underwent RC (203 RARC and 278 ORC). No differences in recurrence-free survival (RFS) were observed: 5-years 70.8% vs. 64.7%, and the 10-year RFS rates were 69.6% vs. 62.7% for the RARC vs. ORC, respectively. No differences in the overall survival (OS) were described between the two groups: 58.9% and 39.9% at 5 and 10 years for RARC and 57.7% and 45.6% at 5 and 10 years for ORC patients (p = 0.466) [20].

Similar results were published in the largest multi-institutional study to date. The International Robotic Cystectomy Consortium (IRCC) reported 5-year recurrence-free, cancer-specific, and overall survival rates of 67%, 75%, and 50%, respectively, which were comparable to ORC series [21,22].

2.4. Complications

In the CORAL RTC (three arm study that compares open, laparoscopic, and robotic cystectomy) the 30-day complication rates (Clavien-Dindo system) between the three different techniques were: Seventy percent for ORC, 55% for RARC and 26% laparoscopic radical cystectomy (LRC) (p = 0.024). These differences are statistically significant only when ORC was compared to LRC (p < 0.01). There was no significant difference in 90 days complication rates between the three arms [1]. No differences were observed between RARC and ORC when Clavien-Dindo grade ≥3 were analyzed: Twenty percent of the cases of each group presented at least one event.

In two studies analyzed in one meta-analysis, Sathianathen et al. [19] revealed that the need for perioperative transfusions was lower for RARC than for ORC (RR 0.58, 95% CI 0.43–0.80). This finding is endorsed by the RAZOR trial where RARC described a significantly lower estimated blood loss (EBL) 300 mL when compared to ORC 700 mL (p < 0.0001), requiring less frequent intraoperative blood transfusions (13% vs. 34%, p < 0.0001) and postoperative blood transfusions (25% vs. 40%, p < 0.0089).

Recently, Moschovas et al. [23] reported a multicentric study evaluating the RARC outcomes and complication rates during the learning curve of surgeons that already had expertise in robotic-assisted radical prostatectomies. Interestingly, the complication rates were similar to the reference centers of radical cystectomies. Therefore, the author concluded that the robotic prostatectomy expertise could minimize the complications during the learning curve of radical cystectomies [23].
Several studies have shown a longer operative time for the RARC, with surgical time ranging from 252 min to 456 min for RARC and 210–329 min for ORC \([9,10,24]\). Similar results were seen in the RAZOR trial, where the median operative time for RARC was 428 min and 361 min for ORC \((p=0.0005)\). This operative time length is related to the type of diversion performed, being the intracorporeal urinary diversion linked to higher operative time \([25,26]\).

2.5. Quality of life (QoL)

Several studies have evaluated the QoL of the patients after RC using validated questionnaires, without finding differences between RARC and ORC \([2,18,24]\). In the RAZOR trial the RARC group, the mean estimated score for emotional wellbeing was significantly higher at 3 months \((p=0.0007)\) and 6 months \((p=0.0014)\) than at baseline. Similarly, in the ORC group, the mean estimated emotional wellbeing score was significantly higher at 3 months \((p=0.0007)\) and at 6 months \((p=0.0007)\) than at baseline. Both groups had significant improvement in mean total Functional Assessment of Therapy-Vanderbilt Cystectomy Index (FACT-VCI) score, 6 months after surgery compared with baseline \([18]\).

Similar results were found by Messer et al. \([27]\) and in the CORAL trial, where using different models of the FACT questionnaire, no difference in the QoL were seen between ORC and RARC.

Furthermore, Stegemann et al. \([28]\) sought to compare patient QoL outcomes at 90 days with baseline (before surgery) using the Convalescence and Recovery Evaluation (CARE). The average time it took for patients to reach 90% in the overall CARE difference index was 63 days.

2.6. Race cost-effectiveness

In a prospective randomized controlled trial with 124 patients, RARC with neobladder had an additional cost of $3,920 compared with ORC \((p<0.0001)\). For RC with an ileal conduit, RARC generated an average additional cost of $1,740 compared with ORC \((p<0.05)\). Additional costs due to RARC were primarily related to operating room costs (robot, supplies, and facilities) and physician costs \([10]\).

In a retrospective observational cohort study using the US Nationwide Inpatient Sample, with 1,444 ORCs and 224 RARCs to compare population-based perioperative outcomes and costs, patients undergoing RARC experienced fewer inpatient complications (49.1% and 63.8%, \(p=0.035\)), fewer deaths (0% and 2.5%, \(p<0.001\)), and less parenteral nutrition use (6.4% and 13.3%, \(p<0.046\)). However, there was no difference in length of stay and RARC was $3,797 more costly when compared with ORC \((p=0.023)\) \([29]\).

Michels et al. \([30]\) showed lower rates of minor and major complications of RARC versus ORC were 18% vs. 23% and 16% vs. 25%, at 30 and 90 days respectively. However, the 30 and 90 days extra costs needed to prevent one major complication were €62,582 and €37,007, respectively \([30]\).

2.7. RC in the elderly

A multicentric European study with prospectively collected data of patients 80 years old or older who underwent RC and ureterocutaneostomy, aimed to assess patient frailty as a risk factor for RC complications, using a simplified frailty index (sFI) with a 5-item score, including diabetes mellitus, functional status, chronic obstructive pulmonary disease (COPD), congestive cardiac failure, and hypertension. Most of the major complications (Clavien-Dindo \(\geq 3\)) occurred in patients with sFI \(\geq 3:13 (11.1%)\) versus 4 \(3.4%; p=0.02\) \([31]\). Similar results were found by Sathianathen et al. \([32]\) using an extended sFI patients with sFI \(\geq 3\) had a greater likelihood of experiencing a major complication (odds ratio 3.22, 95% CI 2.01–5.17), especially in the subgroup of patients aged \(\geq 65\) years.

3. Conclusion

Several studies with level-1 evidence have demonstrated that RARC is technically feasible and safe. Also, the oncological, pathological, and perioperative outcomes are equivalent to ORC. The robotic approach improves some important perioperative outcomes, such as blood loss and transfusion rates. The major drawback is the longer operative time of RARC compared to ORC. However, OT in RARC decreases significantly as the surgeon gain experience.

Author contributions

Study concept and design: Gabriel Ogaya-Pinies, Marcio Covas Moschovas.

Data acquisition: Kulthe Ramesh Seetharam Bhat.

Data analysis: Cathy Jenson.

Drafting of manuscript: Gabriel Ogaya-Pinies, Marcio Covas Moschovas, Cathy Jenson.

Critical revision of the manuscript: Vipul R. Patel.

Conflicts of interest

The authors declare no conflict of interest.

References

[1] Alfred Wittjes J, Lebrecht T, Comperat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2017; 71:462–75.

[2] Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19:666–75.

[3] Barbash GI, Gled S. New technology and health care costs—the case of robot-assisted surgery. N Engl J Med 2010;363:701-4.

[4] Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009;55:164–74.

[5] Luchey AM, Agarwal G, Poch MA. Robotic-assisted radical cystectomy. Canc Contr 2015;22:301–6.

[6] Menon M, Hemal AK, Tewari A, Shrivastava A, Shoma A, El Tabey N, et al. Nerve-sparing robot-assisted radical cystoprostatectomy and urinary diversion. BJU Int 2003;92:232–6.

[7] Wilson TG, Guru K, Rosen RC, Wiklund P, Annerstedt M, Bochner BH, et al. Best practices in robot-assisted radical
cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. Eur Urol 2015;67:363–75.

[8] Parekh DJ, Messer J, Fitzgerald J, Ercole B, Svatek R. Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy. J Urol 2013;189:474–9.

[9] Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, Pruthi RS. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol 2010;57:196–201.

[10] Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Keren Collins J, Patel H, Adding F, Annerstedt M, Dasgupta P, Gaya J, Vila-Reyes H, Gavrilov P, Territo A, Breda A, Palou J, Simone G, Papalia R, Ferriero M, Guaglianone S, Castelli E, Adding C, Collins JW, Laurin O, Hosseini A, Wiklund NP. Prospective randomized controlled trial of robotic versus open assisted radical cystectomy. J Urol 2013;189:474–9.

[11] Collins J, Patel H, Adding F, Annerstedt M, Dasgupta P, Khan SM, et al. Enhanced recovery after robot-assisted radical cystectomy: EAU robotic urology section scientific working group consensus view. Eur Urol 2016;70:649–60.

[12] Gaya J, Vila-Reyes H, Gavrilov P, Territo A, Breda A, Palou J, et al. Robotic radical cystectomy. Arch Esp Urol 2019;72:293–8.

[13] Adding C, Collins JW, Laurin O, Hosseini A, Wiklund NP. Enhanced recovery protocols (ERP) in robotic cystectomy surgery. Curr Urol Rep 2015;16:32. https://doi.org/10.1007/s11934-015-0497-7.

[14] Xu R, Zhao X, Zhong Z, Zhang L. No advantage is gained by preoperative bowel preparation in radical cystectomy and ileal conduit: a randomized controlled trial of 86 patients. Int Urol Nephrol 2010;42:947–50.

[15] Simone G, Papalia R, Ferriero M, Guaglianone S, Castelli E, Collura D, et al. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol 2013;20:390–7.

[16] Hautmann RE, de Petriiconi RC, Pfeiffer C, Volkm KGR. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012;61:1039–47.

[17] Gschwend JE, Heck MM, Lehmann J, Rubben H, Albers P, Wolff JM, et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol 2019;75:604–11.

[18] Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label randomised, phase 3, non-inferiority trial. Lancet 2018;391:2525–36.

[19] Sathianathen NJ, Kalapara A, Frydenberg M, Lawrentschuk N, Weight CJ, Parekh D, et al. Robotic assisted radical cystectomy vs. open radical cystectomy: systematic review and meta-analysis. J Urol 2019;201:715–20.

[20] Faraj KS, Abdul-Muhsin HM, Rose KM, Navaratnam AK, Patton MW, Eversman S, et al. Robot-assisted radical cystectomy vs. open radical cystectomy: over 10 years of the Mayo Clinic Experience. Urol Oncol 2019;19:1078–439.

[21] Raza SJ, Wilson T, Peabody JO, Wiklund P, Scher DS, Al-Daghmin A, et al. Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol 2015;68:721–8.

[22] Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, et al. Radical cystectomy for carcinoma of the bladder: 2720 consecutive cases 5 years later. J Urol 2008;180:121–7.

[23] Moschovas MC, Chade DC, Arap MA, Sarkis AS, Nahas WC, Tanure LHR, et al. Robot-assisted radical cystectomy: the first multicentric Brazilian experience. J Robotic Surg 2020;5:703–8.

[24] Khan MS, Gan C, Ahmed K, Ismail AF, Watkins J, Summers JA, et al. A single-centre early phase randomised controlled three-arm trial of open, robotic, and laparoscopic radical cystectomy (CORAL). Eur Urol 2016;69:613–21.

[25] Hussein AA, May PR, Ahmed YE, Saar M, Wijburg CJ, Richstone L, et al. Development of a patient and institutional-based model for estimation of operative times for robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int 2017;120:695–701.

[26] Collins JW, Hosseini A, Adding C, Nyberg T, Koupparis A, Rowe E, et al. Early recurrence patterns following totally intracorporeal robot-assisted radical cystectomy: results from the EAU Robotic Urology Section (ERUS) Scientific Working Group. Eur Urol 2017;71:723–6.

[27] Messer JC, Punnen S, Fitzgerald J, Svatek R, Parekh DJ. Health related quality of life from a prospective randomized clinical trial of robotic assisted laparoscopic versus open radical cystectomy. BJU Int 2014;114:896–902.

[28] Stegemann A, Rehman S, Brewer K, Kesavadas T, Hussain A, Chandrasekhar R, et al. Short-term patient-reported quality of life after robot-assisted radical cystectomy using the Convalescence and Recovery Evaluation. Urology 2012;79:1274–9.

[29] Yu HY, Hevelone ND, Lipsitz SR, Kowalczyk KJ, Nguyen PL, Choueiri TK, et al. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol 2012;61:1239–44.

[30] Michels CTJ, Wijburg CJ, Leijte E, Witjes JA, Rovers MM, Grutters JPC, et al. A cost-effectiveness modeling study of robot-assisted (RARCe) versus open radical cystectomy (ORC) for bladder cancer to inform future research. Eur Urol Focus 2019;5:1058–65.

[31] De Nunzio C, Ciccone A, Izquierdo L, Lombardo R, Tema G, Genitoriourin Canc 2019;17:402–7.

[32] Sathianathen NJ, Jarosek S, Bolton D, Konety BR. A simplified frailty index to predict outcomes after radical cystectomy. Eur Urol Focus 2019;5:658–63.